Publications
Search results
Jump to search filtersDevelopment of Potent and Effective SARS-CoV-2 Neutralizing Nanobodies
Abstract not provided.
Rapidly Adapting Neutralizing Antibodies to Related Virus Types and Subtypes
Adapting Neutralizing Antibodies to Related Virus Types and Subtypes
Sandia's Research in Support of COVID-19 Pandemic Response: Materials Science
Sandia Materials Science Investment Area contributed to the SARS-CoV-2 virus and COVID-19 disease which represent the most significant pandemic threat in over 100 years. We completed a series of 7, short duration projects to provide innovative materials science research and development in analytical techniques to aid the neutralization of COVID-19 on multiple surfaces, approaches to rapidly decontaminate personal protective equipment, and pareto assessment of construction materials for manufacturing personal protective equipment. The developed capabilities and processes through this research can help US medical personnel, government installations and assets, first responders, state and local governments, and multiple federal agencies address the COVID-19 Pandemic.
Deactivation of SARS-CoV-2 by Boronic Acid-Functionalized Polymer
Boronic acid-modified polymers (BAMPs) can interact with glycoproteins and other glycosylated compounds through covalent binding of the boronic acid moieties to saccharide residues. As a first step toward evaluating the utility of BAMPs as SARS-CoV-2 antiviral agents, this COVID-19 rapid response LDRD was intended to examine the effect of BAMPs on SARS-CoV-2 spike glycoprotein and its subsequent binding with ACE2 receptor protein. Multiple different approaches were attempted in order to determine whether BAMPs based on poly(ethylene glycol) and poly(ethylenimine) bind the spike protein, but failed to produce a definitive answer. However, two different enzyme-linked immunosorbent assays clearly showed no discernable effect of boronic acid in inhibiting spike-ACE2 binding.
Development of Blood Brain Barrier Penetrating Antibody Therapeutics for Encephalitic Alphaviruses
Abstract not provided.
Development of Blood Brain Barrier Penetrating Antibody Therapeutics for Encephalitic Alphaviruses
Abstract not provided.
Characterizing differential expression of transmembrane protein 30A
Abstract not provided.